CEOs Tell Trump Tax Cuts Could Bring More Biopharma Plants To US
Executive Summary
Lower taxes could entice biopharmaceutical sector to focus more on the US as it seeks to expand biotech manufacturing capacity where it can find highly educated and experienced scientists.
You may also be interested in...
A New Start: President Biden Visits Pfizer
President Biden’s relationship with the US pharmaceutical industry is starting out with the starkest contrast imaginable with the initial approach of the Trump Administration – at least on the symbolic level.
Carrots and Stick: Biopharma At The White House
Drug industry executives discuss drug pricing and tax and regulatory reform in a high-profile meeting with President Trump at the White House.
Carrots and Stick: Biopharma At The White House
Drug industry executives discuss drug pricing and tax and regulatory reform in a high-profile meeting with President Trump at the White House.